Zymeworks (ZYME) announced that the waiting period under the Hart-Scott-Rodino, HSR, Antitrust Improvements Act of 1976, as amended, for the previously announced license agreement of zanidatamab, a HER2-targeted bispecific antibody, with Jazz Pharmaceuticals (JAZZ) has expired. The expiration or termination of the HSR waiting period was a condition to Zymeworks’ receipt of a $50M non-refundable upfront payment from Jazz as part of the agreement. Zymeworks anticipates providing Jazz top-line clinical data from Zymeworks’ HERIZON-BTC-01 study before the end of 2022. Should Jazz decide to continue the collaboration following the data readout, a second, one-time payment of $325M to Zymeworks will be due and payable, which Zymeworks expects to receive before the end of 2022.
Published first on TheFly
Read More on ZYME: